Literature DB >> 21269938

Effects of suppressing glucose transporter-1 by an antisense oligodeoxynucleotide on the growth of human hepatocellular carcinoma cells.

Tian-Qi Liu1, Jun Fan, Lin Zhou, Shu-Sen Zheng.   

Abstract

BACKGROUND: The glucose transporter-1 (Glut-1), a key rate-limiting factor in the transport and metabolism of glucose in cancer cells, is over-expressed in many human cancer cells and this over-expression is correlated with poor biological behavior. The increased levels of Glut-1 expression in hepatocellular carcinoma (HCC) cells functionally affect tumorigenicity. This study was undertaken to investigate effects of suppressing Glut-1 by an antisense oligodeoxynucleotide (AS-ODN) on the growth of human hepatocellular carcinoma (HepG-2) cells.
METHODS: We used AS-ODN targeting against the Glut-1 gene in a HepG-2 cell line. There were four experimental groups: empty pcDNA3.1 vector (mock transfection), pcDNA3.1-anti-Glut (+), pcDNA3.1-Glut (+), and non-transfected HepG-2 cells. The Glut-1 mRNA expression was detected by RT-PCR and the Glut-1 protein expression by Western blotting after cell culture, and the glucose uptake was detected after glucose stimulation in each group.
RESULTS: Compared with non-transfected HepG-2 or Glut-1 pcDNA3.1, a down-regulation of Glut-1 mRNA in HepG-2 cells transfected with anti-Glut-1 pcDNA3.1 was noted (P<0.05). Glut-1 protein in HepG-2 cells transfected with Glut-1 AS-ODN was decreased compared with non-transfected HepG-2, Glut-1 pcDNA3.1, or empty vectors. Glucose uptake by the HepG-2 cells transfected with AS-ODN was decreased at 1 hour after glucose stimulation.
CONCLUSIONS: The application of Glut-1 AS-ODN can down-regulate the expression of Glut-1 at mRNA and protein, and inhibit glucose uptake partially in HepG-2 cells. The Glut-1 gene maybe a potential therapeutic target for HCC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21269938     DOI: 10.1016/s1499-3872(11)60010-6

Source DB:  PubMed          Journal:  Hepatobiliary Pancreat Dis Int


  8 in total

1.  Inhibition of glucose-transporter 1 (GLUT-1) expression reversed Warburg effect in gastric cancer cell MKN45.

Authors:  Tian-Biao Zhang; Ying Zhao; Zhao-Xue Tong; Yi-Fu Guan
Journal:  Int J Clin Exp Med       Date:  2015-02-15

Review 2.  Including the mitochondrial metabolism of L-lactate in cancer metabolic reprogramming.

Authors:  Lidia de Bari; Anna Atlante
Journal:  Cell Mol Life Sci       Date:  2018-05-04       Impact factor: 9.261

3.  Co-expression of CD147 and GLUT-1 indicates radiation resistance and poor prognosis in cervical squamous cell carcinoma.

Authors:  Xin-Qiong Huang; Xiang Chen; Xiao-Xue Xie; Qin Zhou; Kai Li; Shan Li; Liang-Fang Shen; Juan Su
Journal:  Int J Clin Exp Pathol       Date:  2014-03-15

4.  Dehydroascorbic Acids-modified Polymer Micelles Target Cancer Cells to Enhance Anti-tumor Efficacy of Paclitaxel.

Authors:  Xiaoyu Pei; Feifei Luo; Jun Zhang; Wulian Chen; Chen Jiang; Jie Liu
Journal:  Sci Rep       Date:  2017-04-20       Impact factor: 4.379

5.  Black bean peptides inhibit glucose uptake in Caco-2 adenocarcinoma cells by blocking the expression and translocation pathway of glucose transporters.

Authors:  Luis Mojica; Diego A Luna-Vital; Elvira Gonzalez de Mejia
Journal:  Toxicol Rep       Date:  2018-04-27

Review 6.  Glycosylated Nanoparticles for Cancer-Targeted Drug Delivery.

Authors:  Sergio Andrés Torres-Pérez; Cindy Estefani Torres-Pérez; Martha Pedraza-Escalona; Sonia Mayra Pérez-Tapia; Eva Ramón-Gallegos
Journal:  Front Oncol       Date:  2020-11-30       Impact factor: 6.244

7.  Effect of antisense oligodeoxynucleotides glucose transporter-1 on enhancement of radiosensitivity of laryngeal carcinoma.

Authors:  Sen-Xiang Yan; Xing-Mei Luo; Shui-Hong Zhou; Yang-Yang Bao; Jun Fan; Zhong-Jie Lu; Xin-Biao Liao; Ya-Ping Huang; Ting-Ting Wu; Qin-Ying Wang
Journal:  Int J Med Sci       Date:  2013-08-21       Impact factor: 3.738

8.  Apigenin inhibits the proliferation of adenoid cystic carcinoma via suppression of glucose transporter-1.

Authors:  Jin Fang; Yang-Yang Bao; Shui-Hong Zhou; Jun Fan
Journal:  Mol Med Rep       Date:  2015-08-20       Impact factor: 2.952

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.